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Abstract
SARS-CoV2 infection has devastating consequences on healthcare systems and 
has caused 3 million deaths by April 2021. Identifying patients at risk of death is 
a priority. Moderate–severe COVID-19 cases seem to associate a cytokine release 
that follows endothelial injury, triggering a hyperinflammatory and procoagulant 
state in which leukocytes and platelets are protagonists. Our group has published 
some reports about the usefulness of the hemogram in COVID-19. Hemogram-
derived ratios, mainly the neutrophil-to-lymphocyte ratio (NLR) and the novelty 
neutrophil-to-platelet ratio (NPR), obtained on admission and their rate of change 
during hospitalization, can easily detect patients with high risk of mortality. 
Hemogram is a tool available to all hospitals and analyzing the hemogram-derived 
ratios would provide much more information than could be extracted by evaluating 
the counts in isolation. We now know that in COVID-19 it is essential to start early 
anti-inflammatory treatment when patient deteriorates and the hemogram could 
be a good indicator of this situation. More comprehensive studies are needed to 
determine how useful these hemogram-derived ratios and prognostic scores are. 
In the next chapter we will present information related to this aspect as well as our 
group’s research on the usefulness of the hemogram in COVID-19.
Keywords: COVID-19, neutrophil-to-platelet ratio, NPR, neutrophil-to-lymphocyte 
ratio, NLR, hemogram-derived ratios
1. Introduction
COVID-19 is a systemic disease, in which all organs can be affected. Several 
studies have emphasized an anomalous immune response as the starting point for 
hypercoagulability phenomena, endothelial damage and macro- and microthrom-
bosis, which would trigger life-threatening consequences in patients. White blood 
cell populations (monocytes, lymphocytes and neutrophils) play a crucial role 
in the systemic inflammatory response and platelets have a direct function in the 
thrombotic response.
Differential blood cell counts can be measured simply, are cost-effective 
and reliable, and therefore can be used as markers of severity of the immune 
and inflammatory, and even the procoagulant response. In this context, white 
blood cells and platelets as circulating biomarkers involved in inflammatory and 
Fighting the COVID-19 Pandemic
2
thrombotic responses could potentially predict clinical outcomes of patients with 
COVID-19.
Various hemogram parameters, including hemogram-derived ratios, have been 
used to try to identify patients with worse prognosis for COVID-19. In the following 
chapter the reader will find information related to this aspect as well as our group’s 
research on the usefulness of the hemogram in COVID-19.
2.  Pathophysiological basis for the potential usefulness of the blood 
count in COVID-19
The clinical presentation of COVID-19, ranges from a mild, self-limited form of 
the disease to multiple organ failure [1–4]. In the most severe cases, the disease can 
lead to severe viral pneumonia with dyspnea and hypoxemia that can evolve into 
severe respiratory distress syndrome, heart failure, obstructive thromboinflam-
matory syndrome, septic shock and multi-organ failure. This rapidly progressive 
deterioration causes the disease even fatal in some patients [5–11].
Several studies have emphasized an anomalous immune response as the start-
ing point of an obstructive thrombo-inflammatory syndrome in which all organs 
can be affected, especially vital organs such as the kidney or the heart, with the 
incidence of pulmonary embolisms being very high in COVID-19 patients [12–14]. 
The most severe middle-aged patients suffered more localized lung damage and 
coagulopathy [14].
Some of the variables that have shown significant correlation with poor out-
comes in COVID-19 include male sex, older age, smoking status, and the coex-
istence of comorbidities such as obesity, hypertension, diabetes, cardiovascular 
disease, cerebrovascular disease, chronic kidney disease, chronic obstructive 
pulmonary disease, hepatitis B infections and malignancy [1, 11].
Analytical parameters have also been widely used in early evaluation and moni-
toring of COVID-19 patients. Many of these parameters, specifically derived from 
white blood cell or platelet count values, provide information on both immunologi-
cal status and hemostasis in response to SARS-CoV-2 infection.
In fact, the host’s inflammatory response to SARS-CoV-2 infection appears 
critical in clinical evolution of COVID-19, and blood cell interactions are essential 
in the pathophysiology of inflammation, immune responses and hemostasis in this 
setting.
These interactions are complex, and it is often difficult to discriminate the  
specific roles of each cell type in the different phases of the same disease. Platelets 
are the main mediators of hemostasis while leukocytes are responsible for the 
immune responses.
White blood cell populations (monocytes, lymphocytes and neutrophils) are 
the main protagonists in the systemic inflammatory response to severe infection, 
injury, trauma and shock and therefore can be used as markers of this response [15]. 
Neutrophils are the most abundant white blood cells in circulation and represent the 
first line of innate immune defense, playing a fundamental role [7]. Furthermore, 
when this cell type is active, it has migratory capacity from the venous system to the 
affected organ or systems [11].
Accumulating evidence suggests that a portion of patients presenting with 
severe COVID-19 may have an underlying hyperinflammatory response that drives 
a cytokine release storm resulting in multiorgan failure and death [16]. A novel 
form of microvascular obstructive thromboinflammatory syndrome has been 
proposed as the pathophysiology underlying this hyperinflammatory response. 
Following SARS-CoV-2 infection, CD4+ T lymphocytes are rapidly activated to 
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become pathogenic T helper 1, cells that produce cytokines that stimulate inflam-
matory CD14 + CD16+ monocytes generating IL-6 expression and accelerating the 
inflammatory process [17]. The inflammatory response may stimulate neutrophil 
production and even accelerate lymphocyte apoptosis.
Autopsies of patients affected by COVID-19 revealed a significant infiltration 
of neutrophils in the pulmonary capillaries with extravasation towards the alveolar 
lumen. This existence of acute capillaritis together with the presence of tracheal 
neutrophilic mucositis demonstrates the existence of a general inflammation of the 
airways [7].
Neutrophils can release large amounts of oxygen free radicals, which induce 
cell damage and release of viral particles from cells. Antibody-dependent cells can 
directly destroy the virus by exposing the viral antigen and thus activating cell-
specific and humoral immunity. Neutrophils are also capable of producing large 
amounts of cytokines and signaling molecules such as endothelial growth factors 
(VEGF). Two of these factors, VEGF-A and VEGF-C, present significantly higher 
values in COVID-19 patients [11]. The accumulation of neutrophils associated with 
endothelial cell infection in COVID-19 disease induces endothelitis in different 
organs, thus contributing to systemic damage due to hypoxic microcirculation 
failure [7]. Increased neutrophils is an important risk factor and is closely related to 
increased patient severity, the development of acute respiratory syndrome (ARDS), 
and death in COVID-19 patients [18].
Infected pulmonary macrophages produce TNF-α and interleukins that cause 
T-cell apoptosis and lymphocyte recirculation, with massive recruitment into 
inflamed tissues [19, 20]. In addition, it is known that SARS-CoV-2 can directly 
infect lymphocytes, which have the angiotensin-converting enzyme 2 (ACE 2) 
receptor, so the virus can cause a decrease in their count, especially TCD8 + and 
TCD4 + lymphocytes [21, 22]. This triggers global lymphopenia, common in 
patients with severe COVID-19. It has been shown that the lower the lymphocyte 
count and the longer the duration of lymphopenia, the more severe the condition of 
infected patients and the worse the prognosis [19, 20].
Dysregulated immune cell responses are thought to play a notable role in the 
severity of disease [23]. Severe inflammatory responses result in a weak adaptive 
immune response, which translates into an imbalance of the immune response.
Several studies have shown that patients with COVID-19 who have higher levels 
of inflammatory cytokines and chemokines have greater disease severity, sug-
gesting the involvement of cytokine storm in severe forms of the disease [1, 24]. 
This uncontrolled cytokine production, which increases as the infection worsens, 
provides the setting for SARS-CoV-2 pathogenesis leading to viral sepsis, tissue dam-
age, disseminated intravascular coagulation, shock and even multi-organ failure. 
Proinflammatory cytokines induce apoptosis in lung epithelial cells, dendritic cells 
and macrophages, which impairs the pulmonary microvascular barrier and alveolar 
gas exchange. They increase vascular permeability, as well as the amount of fluid and 
inflammatory cells in the alveoli, causing dyspnea and respiratory failure [24, 25].
It has been hypothesized that an endothelial thromboinflammatory syndrome 
is triggered after alveolar viral damage [26]. SARS-CoV-2 uses the cell surface 
ACE 2 receptor to enter the interior of cells. ACE 2 is expressed in several organs, 
including endothelial cells [21, 22]. It has been reported that SARS-CoV-2 can infect 
genetically modified human blood vessel organoids in vitro, and the involvement of 
endothelial cells in the vascular beds of different organs has also been demonstrated 
in necropsies performed on deceased COVID-19 patients [27, 28].
Endothelial cell damage may be an important trigger of cytokine discharge, 
and moderate and severe COVID-19 cases appear to be associated with a large 
release of cytokines, leading to a hyperinflammatory and procoagulant state. Such 
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inflammation, associated with the disproportionate cytokine storm, spreads widely 
through the systemic circulation, affecting different organs with high mortality [29].
This procoagulant state is associated with thromboembolic phenomena, such 
as deep vein thrombosis and pulmonary thromboembolism, which carry a worse 
prognosis. Anatomopathological studies of the lungs of patients with COVID-19 
have shown frequent and systematic findings of thrombotic microangiopathy and 
hemorrhage [30, 31].
This new form of microvascular obstructive thromboinflammatory syndrome 
has been proposed as the pathophysiological basis underlying this hyperinflamma-
tory response. This endothelial thromboinflammatory syndrome can progressively 
involve the microvascular bed of several vital organs, leading to multiple organ 
failure and death [26].
In addition, individuals with pre-existing endothelial dysfunction and therefore 
with a more active base inflammatory state, could lead to worse evolution in COVID-
19. It has been observed that those patients affected by COVID-19 and with cardio-
vascular diseases had a greater probability of suffering myocardial injuries than those 
who did not present this type of previous injuries. Furthermore, those patients with 
chronic obstructive pulmonary disease (COPD) had a greater probability of suffering 
pulmonary coinfections and septic shock. Moreover, patients with previous kidney 
disease are also susceptible to developing COVID-19-induced worsening of kidney 
disease. The presence of these comorbidities may have increased mortality indepen-
dently of COVID-19 infection as a result of the worsening of comorbidities induced 
by the viral infection rather than by the direct damage produced by SARS-CoV-2 [14].
In this context, white blood cells and platelets would have a direct role in this 
inflammation and in the thrombotic response; therefore, circulating biomarkers 
representing inflammation and immune status could potentially predict clinical 
outcomes of COVID-19 patients [11, 32].
Following these findings, routine blood tests and differential white blood cell 
counts are easy to obtain at most healthcare centers and are affordable and cheap 
markers for predicting a worse prognosis in COVID-19.
Several studies have reported the results of blood tests in patients with COVID-19, 
and most severe cases present low lymphocytes counts, higher leukocytes counts and 
hemogram-derived ratios, as well as lower percentages of monocytes, eosinophils and 
basophils [24]. Some of these inflammatory markers have been evaluated and found 
to correlate with worse prognosis, including peripheral white blood cell count and 
hemogram-derived ratios.
3. Hemogram-derived ratios in COVID-19
The hemogram-derived ratios are parameters which amplify the value of 
neutrophils, platelets and lymphocytes and could be useful to predict prognosis 
and severity of the disease. Several hemogram-derived ratios as neutrophil-to-
lymphocyte ratio (NLR), derived NLR ratio (dNLR) (neutrophil count/leukocyte 
count−neutrophil count), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-
monocyte ratio have been used as inflammatory markers of COVID-19 [11, 32–34].
3.1 Neutrophil-to-lymphocyte ratio (NLR)
An available marker of great value for measuring the inflammatory status of 
an individual is the NLR, an easily measurable parameter that is obtained from a 
routine blood test. It is the ratio of the absolute neutrophil count to the absolute 
lymphocyte count of a routine blood count [33, 35, 36].
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It has been proposed as a prognostic marker of severity in many pathologies such 
as oncological processes, septic shock, infectious diseases, intracranial hemorrhage 
and cardiovascular disease among others [35, 36].
Moreover, NLR appears to be an indicator of endothelial dysfunction and an 
important predictor of cardiovascular mortality [23, 24].
The endothelial dysfunction could be one of the aggravating factors of SARS-
CoV-2 disease and would explain the evolution of the disease towards multiple 
organ failure [37–40]. Several studies have been published, incorporating NLR as a 
marker of poor prognosis in patients with COVID-19 [8, 11, 33, 41, 42].
The normal values of this quotient in an adult population, excluding the geriat-
ric population, are around 0.78 and 3.5. When the NLR result exceeds the normal 
maximum value, the probability of the disease going from a mild–moderate to a 
severe state dramatically increases.
A higher NLR value at admission is related to mortality in COVID-19, since high 
values have been observed at the beginning of admission in patients who did not 
survive [37]. This is because in more severe patients, the inflammatory response 
stimulates neutrophil production and therefore the neutrophil count is higher, 
while this response accelerates lymphocyte apoptosis and the lymphocyte count is 
low, and therefore the NLR value increases.
Our group has investigated the usefulness of this ratio being one of the first 
groups to publish on the implications of this ratio and its relationship with worse 
prognosis in COVID-19. In a small cohort of patients, we demonstrated how the 
evolution of NLR in terms of rate of increase and Peak NLR was associated with 
worse outcomes in COVID-19 with higher risk of ICU admission or death [38].
Subsequently, in a cohort of more than 2000 patients, we demonstrated that 
NLR is associated with in-hospital mortality as it is higher at baseline hospital 
admission and maintains significance after multivariable adjustment [43].
Moreover, patients requiring ICU admission had significantly higher NLR values 
at the time of hospital admission [44].
3.2 Platelet-to-lymphocyte ratio (PLR)
Some studies demonstrate the ratio of platelet count to lymphocyte count, called 
PLR, as a reliable marker of immune-mediated, metabolic, prothrombotic and 
neoplastic diseases.
Its use in combination with other complementary hematological ratios, in 
particular NLR, provides additional information on the degree of disease activity 
and helps to monitor the response to anti-inflammatory treatments. It could even 
help in the early detection of comorbidities that develop in the course of disease 
treatment [45–47].
PLR primarily reflects the level of systemic inflammation that translates megakaryo-
cyte activity in the hematopoietic tissue of the bone marrow, an important component 
in thrombosis. It also plays a very important role in the inflammatory response by pro-
moting the recruitment of neutrophils and other inflammatory cells to the site of injury.
This ratio reflects both aggregation and inflammatory pathways and is therefore 
considered by some authors to be more valid for predicting inflammatory pathology 
than platelet or lymphocyte counts alone [11]. However, relationship between PLR 
and mortality has been less explored.
It has been postulated that PLR may reflect the degree of cytokine release, which 
could be a useful indicator of the clinical course of COVID-19 patients [48]. SARS-
CoV-2 infection causes a cytokine storm in body fluids, aggravating the patient’s 
inflammatory response and stimulating platelet release. Some authors consider 
that platelet number and its dynamic changes during the course of COVID-19 and 
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treatment may correlate with cytokine storm, and consequently, with disease sever-
ity and prognosis [48].
Our group has also investigated the usefulness of this ratio in COVID-19 and 
we observed that patients who died presented significantly higher PLR compared 
with patients who survived at admission [43], like patients requiring ICU admission 
[44], but they did not maintain significance after more complex model of multi-
variable adjustment.
3.3 Systemic immune-inflammation index (SII)
The systemic immune-inflammation index (SII) is a hemogram-derived ratio 
defined as the count of neutrophils multiplied by the count of platelets and divided 
by the count of lymphocytes.
SII has recently been proposed as a prognostic indicator in the follow-up of 
patients with sepsis [49] and cancer patients [50, 51] as an index defining the 
instability in the inflammatory response.
This quotient derived from the hemogram has also been studied by our group 
in patients affected by COVID-19 and, like PLR, SII on admission is significantly 
higher in COVID-19 patients who died and required admission to the ICU, but it did 
not maintain statistical significance after multivariate adjustment [43, 44].
3.4 Neutrophil-to-platelet ratio (NPR)
The modulatory interaction between neutrophils and platelets has previously 
been described [52] and based on the biological plausibility of higher total neu-
trophils count and lower total platelets count observed among the most severe 
COVID-19 cases compared to more mild ones, we have investigated the utility of a 
novel parameter, the neutrophil–platelet ratio (NPR).
NPR is the ratio between the count of neutrophils (x 109 cells/L) and the count 
of platelets (x 1011cells/L), and may be useful in signaling a combination of hyper-
inflammatory response and microvascular occlusion that has been identified in 
moderate to severe COVID-19 cases [26, 53].
We hypothesize that a damaged and activated endothelium may increase the 
permeability and release of cytokines that would initiate chemotaxis of inflamma-
tory cells and also recruit other blood cells.
In this context, activated platelets and neutrophils play a determining role in 
microvascular occlusion during the thromboinflammatory phase of the disease 
[54]. These findings were observed in the most severe COVID-19 cases who died, 
especially higher neutrophil and lower platelet counts.
Our results have shown that NPR levels were significantly associated with in-
hospital mortality due to COVID-19 and their association remained significant even 
after multivariable adjustment.
Also, higher levels of NPR at admission are related to higher risk of ICU admis-
sion in COVID-19 patients [43, 44].
We are the first group in the world reporting the usefulness of this hemogram-
derived ratio in a disease and we believe that this novel finding merits further 
investigation.
3.5 Incorporation of rates of change of hemogram-derived ratios
Our group has also studied the rate of change in the ratios derived from 
the blood count during the first days of hospitalization in patients affected by 
COVID-19.
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The rate of increase has been shown to be a useful marker of severity and is 
associated with mortality.
Undoubtedly, these rates of change could be affected by the course of COVID-19 
and the treatments applied, but we hypothesized that some of these rates could be 
a valuable parameter in the control of patients without additional risk factors to 
assess modifying the treatment [38, 43, 44].
3.6  Incorporation of hemogram-derived ratios into clinical judgment 
nomograms
In most cases, the first assessment for a COVID-19 case takes place in the 
emergency department, where it is routine clinical practice to carry out a full 
blood panel.
Based on the usefulness of the hemogram-derived ratio, we have developed 
the Risk Score for Predicting In-Hospital Mortality in COVID-19 (RIM Score 
COVID) [53].
We have developed four models: two with NLR, the ratio more widely reported, 
and two with NPR, the novel hemogram-derived-ratio proposed by our group. 
No significant differences were found between NLR and NPR models; however, 
models using the NPR ratio showed more robustness in more complex multivariate 
analyses.
The RIM Score COVID includes following variables at hospital admission: age, 
sex, oxygen saturation, level of C-reactive-protein, NPR and NLR.
The AUC of models including NLR and NPR were evaluated for predicting 
in-hospital mortality by COVID-19 and both performed similarly in the validation 
cohorts: NLR 0.856 (95% CI: 0.818–0.895), NPR 0.863 (95% CI: 0.826–0.901).
Moreover, we have developed two models incorporating the rate of changes of 
both hemogram-derived ratios during the first week after admission, called Velocity 
of NLR (VNLR) and Velocity of NPR (VNPR).
The accuracy of the models were also evaluated for predicting in-hospital 
mortality by COVID-19 and the predictive ability of in-hospital mortality in both 
models improved slightly in the validation cohorts with respect to the values 
obtained at admission: VNLR 0.885 (95% CI: 0.885–0.919), VNPR 0.891 (95% CI: 
0.861–0.922).
According to our results, the RIM Score COVID models are useful for predicting 
the risk of in-hospital mortality from COVID-19.
The proposed RIM Score is a simple and widely available tool that can help 
identify patients at risk of fatal outcomes.
The parameters used in the nomogram are objective, easy to obtain and repro-
ducible in most healthcare facilities without additional cost or need for additional 
laboratory equipment.
These assessments provide a highly accurate predictive value of in-hospital 
mortality risk from COVID-19 [53].
4. Conclusions
The hemogram is an easily measurable, readily available, cost-effective and reli-
able test that could be very useful in establishing the risk of in-hospital mortality on 
hospital admission and in guiding therapeutic decisions in patients with COVID-19.
In this sense, the hemogram is a tool available to all healthcare centers that do 
not have the technical and material means to perform complex immunological 
studies, which usually involve late results.
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The combination of hemogram parameters and blood cell count ratios in 
COVID-19 patients could be a useful combined indicator of host immune and 
inflammatory status.
The ratios derived from the hemogram at the time of hospital admission and 
its increasing trend during the first days of hospitalization have shown their value 
in identifying patients with COVID-19 who have a worse evolution and could be 
useful as prognostic markers of the disease.
The NLR and the novelty NPR have been shown to be independent markers of 
mortality and worse prognosis in patients with COVID-19. These ratios should be 
included in future prospective studies and it would be advisable to start using them 
by physicians in the first evaluation of patients with COVID-19 in the emergency 
department to demonstrate their clinical utility.
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